Kymera appoints Felix J. Baker as director and Lead Independent Director

Kymera Therapeutics, Inc.

Felix J. Baker appointed to Board as Class II director effective March 28, 2024; also named Lead Independent Director.
Dr. Baker is managing member of Baker Bros. Advisors LP, which is affiliated with shareholders holding >5% of stock.
Baker affiliates purchased 4,950,495 pre-funded warrants at $25.2499 each in January 2024; Dr. Baker deemed beneficial owner.
Compensation: option to purchase 32,000 shares at closing price on March 28, vesting over 3 years; annual retainer $60,000 as Lead Independent Director.
Board determined Dr. Baker independent under Nasdaq standards; committee assignments pending.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Felix J. Baker

Director and Lead Independent Director

KYMR · Kymera Therapeutics, Inc.

Effective: 2024-03-28
Filed: April 1, 2024, 7:59 PM ET

On March 28, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”), the Board appointed Felix J. Baker, Ph.D. to join the Board, effective March 28, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Felix J. Baker was appointed as Director and Lead Independent Director at Kymera Therapeutics, Inc..

Action: appointed
Role: Director and Lead Independent Director

Exact text from the filing

On March 28, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”), the Board appointed Felix J. Baker, Ph.D. to join the Board, effective March 28, 2024.

View on SEC.gov

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-082641

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.